Encorafenib and Cetuximab FDA Approval: A Breakthrough Targeted Therapy for Colorectal Cancer
Introduction Colorectal cancer remains one of the leading causes of cancer-related deaths worldwide. Over the past decade, advancements in targeted therapies have significantly improved survival outcomes for patients with specific genetic mutations. One of the most important developments in this field is the encorafenib and cetuximab FDA approval, which offers a targeted treatment option for …